VRC 310: An Open-Label, Randomized Ph I: Healthy Adults of Prime-Boost Intervals w/Monovalent Influenza Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc), Administered Alone or Following Recombinant H5 DNA Vaccine.
Phase of Trial: Phase I
Latest Information Update: 03 Feb 2017
At a glance
- Drugs Influenza A virus vaccine-H5N1 (Primary) ; VRC-AVIDNA036-00-VP (Primary)
- Indications Influenza A virus H5N1 subtype; Influenza virus infections
- Focus Adverse reactions; Pharmacodynamics
- 14 Dec 2011 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 30 Mar 2010 New trial record